WO2021226442A3 - Therapeutic uses of c3-binding agents - Google Patents

Therapeutic uses of c3-binding agents Download PDF

Info

Publication number
WO2021226442A3
WO2021226442A3 PCT/US2021/031268 US2021031268W WO2021226442A3 WO 2021226442 A3 WO2021226442 A3 WO 2021226442A3 US 2021031268 W US2021031268 W US 2021031268W WO 2021226442 A3 WO2021226442 A3 WO 2021226442A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding agents
therapeutic uses
inhibiting
treating
development
Prior art date
Application number
PCT/US2021/031268
Other languages
French (fr)
Other versions
WO2021226442A2 (en
Inventor
Zhonghao LIU
Hui Tian
Original Assignee
Ngm Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals, Inc. filed Critical Ngm Biopharmaceuticals, Inc.
Publication of WO2021226442A2 publication Critical patent/WO2021226442A2/en
Publication of WO2021226442A3 publication Critical patent/WO2021226442A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure generally relates to methods of treating, preventing, or inhibiting the development of respiratory illness (e.g., a severe respiratory illness) and similar respiratory diseases. In addition, the disclosure relates to treating, preventing, or inhibiting the development thrombosis and resulting sequelae such as stroke. The methods comprise administering agents that bind complement component C3 (C3), particularly antibodies that bind human C3.
PCT/US2021/031268 2020-05-08 2021-05-07 Therapeutic uses of c3-binding agents WO2021226442A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063022121P 2020-05-08 2020-05-08
US63/022,121 2020-05-08

Publications (2)

Publication Number Publication Date
WO2021226442A2 WO2021226442A2 (en) 2021-11-11
WO2021226442A3 true WO2021226442A3 (en) 2021-12-30

Family

ID=76181277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/031268 WO2021226442A2 (en) 2020-05-08 2021-05-07 Therapeutic uses of c3-binding agents

Country Status (1)

Country Link
WO (1) WO2021226442A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240117157A (en) * 2021-12-22 2024-07-31 씨디알-라이프 아게 Anti-C3 antibodies and antigen-binding fragments thereof and their use for treating the eye or ocular diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195136A1 (en) * 2018-04-03 2019-10-10 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195136A1 (en) * 2018-04-03 2019-10-10 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTONIO RISITANO: "Complement as a target in COVID-19?", NATURE REVIEWS | IMMUNOLOGY, 23 April 2020 (2020-04-23), XP055860365, Retrieved from the Internet <URL:https://www.nature.com/articles/s41577-020-0320-7.pdf> [retrieved on 20211111] *
MASTAGLIO SARA ET AL: "The first case of COVID-19 treated with the complement C3 inhibitor AMY-101", CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 215, 29 April 2020 (2020-04-29), XP086176895, ISSN: 1521-6616, [retrieved on 20200429], DOI: 10.1016/J.CLIM.2020.108450 *

Also Published As

Publication number Publication date
WO2021226442A2 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
MX2024002152A (en) Anti-ccr8 antibodies and uses thereof.
EP4276114A3 (en) Cd20 binding single domain antibodies
WO2003000714A3 (en) Compositions and methods for preventing protein aggregation in neurodegenerative diseases
WO2004016750A3 (en) FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
TW200603746A (en) Iron sulfate based phosphate adsorbent
GB0229733D0 (en) Hair treatment compositions
BG108443A (en) Substituted oxazoliidinones for combinational therapy
WO2017022962A8 (en) Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient
WO2003092624A3 (en) Use of heat shock proteins to enhance efficacy of antibody therapeutics
WO2019045248A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
ATE411032T1 (en) USES OF CHITOSANOLIGOSACCHARIDES
MX2020008208A (en) Fibroblast binding agents and use thereof.
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2022167816A3 (en) Antibodies
WO2007014943A3 (en) Therapy for neurological diseases
WO2021226442A3 (en) Therapeutic uses of c3-binding agents
MX2012001708A (en) Humanized anti-amyloid-î oligomer antibody.
MX2024005453A (en) Compositions and treatments with nirogacestat.
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
WO2003059260A3 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
JP2004511492A5 (en)
DE602006020838D1 (en) MEDICAMENTS FOR PREVENTING OR TREATING HEART FAILURE WITH AN ANTICHOLINERGICUM
EA200400436A1 (en) MEDICATIONS FOR THE PREVENTION AND TREATMENT OF BROMIDROSIS
EA200300639A1 (en) USE OF SARP-1 FOR THE TREATMENT AND / OR PREVENTION OF SCLERODERMIA
WO2022058618A3 (en) Sars-cov2 antibodies

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21728753

Country of ref document: EP

Kind code of ref document: A2